Replies to post #226257 on Biotech Values

[DewDiligence]

What is the case for continuing to own ENTA as a standalone company at this valuation, other than buyout vig?

If a company has buyout vig at a sizable premium to the current share price, it follows that the valuation is compelling. It’s really that simple, IMO.